A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 351 participants.
Also called NCT07775404
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 351 participants
- Sponsor
- Registry
-
NCT07775404
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China, Hong Kong SAR China, Malaysia, Philippines, Thailand
- Registry status
- Recruiting
Technical summary
Registry record NCT07775404. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2028-04-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus
- Acronym
- Elecoglipron
- Condition
- Obesity
- Condition
- Overweight
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07775404- Content hash
6be0ff146f9f7415c52a2aff37ff57f23193b73f24910cd6ec10382bee0dadd8